Vivos Therapeutics VVOS

$ 4.96 6.44%

Quarterly report 2024-Q3
added 11-14-2024

Vivos Therapeutics Balance Sheet 2011-2024 | VVOS

Annual Balance Sheet Vivos Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	31 K	-1.11 M	-22.5 M	-16.9 M	3.24 M	-568 K	-	-	-	-	-	-	-
Long Term Debt	1.2 M	1.99 M	298 K	423 K	-	525 K	-	-	-	-	-	-	-
Long Term Debt Current	474 K	419 K	1.26 M	867 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	587 K	1.4 M	1.22 M	-	-	-	-	-	-	-
Total Current Liabilities	7.29 M	6.81 M	7.51 M	7.82 M	-	-	-	-	-	-	-	-	-
Total Liabilities	10.3 M	8.92 M	8.15 M	8.41 M	10.5 M	3.38 M	-	-	-	-	-	-	-
Deferred Revenue	2.1 M	2.93 M	2.4 M	2.94 M	2.95 M	890 K	-	-	-	-	-	-	-
Retained Earnings	-93.1 M	-79.5 M	-55.6 M	-35.3 M	-23.3 M	-12.5 M	-	-	-	-	-	-	-
Total Assets	10.7 M	13.7 M	33.7 M	25.3 M	7.55 M	8.2 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	1.64 M	3.52 M	24 M	18.2 M	-	-	-	-	-	-	-	-	-
Book Value	411 K	4.8 M	25.5 M	16.9 M	-2.94 M	4.83 M	-	-	-	-	-	-	-
Total Shareholders Equity	411 K	4.8 M	25.5 M	16.9 M	-2.94 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Vivos Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	1.2 M	1.2 M	1.4 M	1.2 M	1.2 M	1.2 M	-	1.99 M	2.4 M	2.52 M	1.85 M	641 K	1.27 M	641 K	106 K	423 K	423 K	423 K	423 K	3.71 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	7.68 M	9.5 M	11.2 M	10.3 M	10.3 M	11.6 M	-	8.92 M	8.54 M	9.54 M	8.7 M	8.15 M	8.56 M	8.15 M	7.61 M	8.41 M	8.41 M	8.41 M	8.41 M	9.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	1.3 M	1.8 M	2.4 M	2.14 M	2.4 M	2.4 M	-	2.93 M	2.4 M	2.1 M	2.34 M	2.4 M	3.7 M	2.4 M	2.8 M	2.94 M	2.94 M	2.94 M	2.94 M	2.95 M	-	-	-	890 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-101 M	-98.7 M	-96.8 M	-93.1 M	-88.8 M	-86.7 M	-	-79.5 M	-73.4 M	-67.9 M	-61.1 M	-55.6 M	-48.2 M	-55.6 M	-38.7 M	-35.3 M	-35.3 M	-35.3 M	-35.3 M	-23.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	15.3 M	15.8 M	11.8 M	10.7 M	10.3 M	13.7 M	-	13.7 M	18.4 M	24.4 M	29.6 M	33.7 M	41 M	33.7 M	22 M	25.3 M	25.3 M	25.3 M	25.3 M	7.55 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	6.31 M	6.9 M	2.61 M	1.64 M	988 K	3.94 M	200 K	3.52 M	6.72 M	12.7 M	17.8 M	24 M	28.5 M	24 M	14.1 M	18.2 M	18.2 M	18.2 M	18.2 M	469 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	7.66 M	6.35 M	582 K	411 K	46 K	2.11 M	-	4.8 M	9.86 M	14.8 M	20.9 M	25.5 M	32.5 M	25.5 M	14.3 M	16.9 M	16.9 M	16.9 M	16.9 M	-1.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	7.66 M	6.35 M	582 K	411 K	46 K	2.11 M	6.99 M	4.8 M	9.86 M	14.8 M	21 M	25.5 M	32.5 M	25.5 M	14.3 M	25.6 M	16.9 M	16.9 M	16.9 M	-2.94 M	-	-	-	4.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency